143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry
Sajjad Ghane Ezabadi,Azadeh Ebrahimitirtashi,Zahra Salehi,Naghmeh Abbasi Kasbi,Faezeh Khodaie,Mohammad Mehdi Naghizadeh,Seyed Massood Nabavi,Nahid Beladi Moghadam,Mohammad Ali Sahraian,Sharareh Eskandarieh
DOI: https://doi.org/10.1016/j.msard.2024.106104
IF: 4.808
2024-12-15
Multiple Sclerosis and Related Disorders
Abstract:Background/Objective(s) The selection of an appropriate disease-modifying drug (DMD) is crucial for managing the progression of multiple sclerosis (MS), enhancing the quality of life, and addressing the economic implications for patients with multiple sclerosis (PwMS). Changes in DMD—whether through discontinuation or switching—are prevalent, often driven by factors such as insufficient efficacy, adverse effects, and patient intolerance. Despite the significance of this issue, there has been a lack of research focusing on the patterns and determinants of DMD changes specifically among Iranian PwMS. Material(s) and Method(s) This cross-sectional study encompassed all PwMS in Tehran who had altered their DMD regimen within the five years leading up to June 2022. Data were sourced from the nationwide MS registry of Iran (NMSRI) and enriched through additional information gathered via telephone interviews. The study employed structured questionnaires that captured demographic information, disease history, diagnostic details, disease progression, and treatment specifics. DMDs were classified into ten distinct categories, and participants were asked to specify their reasons for treatment modifications. Statistical analyses were performed using IBM SPSS software (version 23), and the study adhered to the ethical standards outlined in the Declaration of Helsinki. Result(s) A total of 2,771 PwMS were included in the analysis, with a female-to-male ratio of 3.3:1. The mean current age of participants was 37.07 years (SD = 9.45), while the mean age at onset was 28.69 years (SD = 8.75). A significant majority (84.5%) of participants had an expanded disability status scale (EDSS) score of ≤5.5, whereas 28.0% reported experiencing a relapse in the year preceding their DMD change. Notably, 70.3% of participants underwent a DMD change, primarily due to poor disease control or relapse. Interferon β-1a and β-1b emerged as the most commonly utilized and modified DMDs, while ocrelizumab and rituximab were the least frequently altered. Oral DMDs, such as fingolimod, exhibited a higher modification rate attributed to side effects. Demographic factors did not correlate with DMD changes; however, individuals with progressive MS, EDSS scores ≥5.5, higher relapse rates, and motor symptoms at disease onset demonstrated significantly elevated rates of DMD modifications. Early-onset MS cases showed increased changes with traditional injectables and dimethyl fumarate, whereas late-onset cases were more likely to switch to fingolimod and natalizumab. Conclusion(s) The findings indicate that DMD changes are influenced by a complex interplay of clinical factors, underscoring the necessity for personalized treatment strategies to optimize patient outcomes. By comprehensively understanding the patterns and underlying reasons for DMD modifications, healthcare providers can make more informed treatment decisions, ultimately enhancing the management of multiple sclerosis in Iranian patients. This research contributes to the growing body of knowledge aimed at improving therapeutic approaches and patient care in the context of MS.
clinical neurology